CYTOO

CYTOO, a company that specializes in micropattern-enhanced cell-based assays, Cenix BioScience, a pioneer in developing HCS applications of RNAi, and three European academic partners to challenge the current limits of HT RNAi cell screening.

Grenoble, France – CYTOO SA announced today the closing of a series C funding round of USD 10M (EUR 7M). New investors, Sham and Entrepreneurs Fund (EF), led the round. Existing investors AURIGA Partners and Jacques Lewiner also participated.

CYTOO sponsors the first edition of the World Cell Race. Organized by a network of researchers in partnership with the American and the French Cell Biology Societies, this unique competition will involve cells coming from labs all around the globe.

CYTOO Cell Architects today announced the commercial release of CYTOOplates™ 96 that bring robustness, sensitivity and powerful quantification to cell-based assays and High Content Screening.

CYTOO SA, a provider of innovative enabling technologies for high content cell analysis, premiered what it believes is the world's first commercially available portfolio of cell adhesive micropattern products to the cell biology research community.